Cite
HARVARD Citation
de Vos, S. et al. (2018). Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Annals of oncology. pp. 1932-1938. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
de Vos, S. et al. (2018). Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Annals of oncology. pp. 1932-1938. [Online].